Military personnel repeatedly exposed to blasts show increased brain inflammation and structural changes

The brains of special warfare community personnel repeatedly exposed to blasts show increased inflammation and structural changes compared with a control group, potentially increasing the risk of long-term, brain-related disease, according to a new study.

Otsuka wins FDA breakthrough therapy designation for IgAN drug – Pharmaceutical Technology

Share this article The FDA has granted breakthrough therapy designation following positive Phase II data released in November. Credit: grandbrothers via Shutterstock. After a high-profile

February 16, 2024

Zebrafish could be used to explore the underlying mechanisms of Nager syndrome

Nager syndrome, or NS, is a rare genetic disease that affects the development of the face and limbs, usually causing anomalies in the bone structures

October 16, 2024

Fresh off ALS drug withdrawal, Amylyx touts interim rare disease data for the same therapy

A week after voluntarily pulling its ALS drug off the market following a failed Phase 3 trial, Amylyx Pharmaceuticals outlined a new direction for the drug by

April 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.